Otsuka extends Penwest collaboration
This article was originally published in Scrip
Executive Summary
Japan's Otsuka Pharmaceuticalhas extended its alliance with Penwest Pharmaceuticals to include a second unidentified compound, to which Penwest will apply its proprietary TIMERx formulation technology. The oral controlled-release delivery system is applicable to a range of products and allows less frequent dosing. The US firm will receive undisclosed fees and other payments as part of the agreement, which it will use to support the development of its in-house pipeline.
You may also be interested in...
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.